Singapore, Sept. 17 -- WuXi XDC Cayman Inc., a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specialising in antibody-drug conjugates (ADCs) and other bioconjugates, has announced an out-licensing collaboration with Ona Therapeutics on WuXi XDC's proprietary WuXiTecan-2 payload-linker technology platform. Ona Therapeutics is a global biotechnology company pioneering first-in-class ADCs to address treatment-resistant cancers.

Under the terms of the agreement, China-based WuXi XDC will grant Ona Therapeutics an exclusive global license to its proprietary WuXiTecan-2 payload-linker technology for the development of an ADC candidate against a single target.

Ona Therapeutics will combine its first-in-c...